Open an account

Sorrento Therapeutics

SRNE · OTC

$0.0008+$0.0006 (+300.00%)TodayMarket closed ·
Prev close $0.0002

About SRNE

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.

Employees
949
Headquarters
San Diego, California
Listed
Jan 19, 2007
Sector
Health Care
Industry
Biotechnology
Website
sorrentotherapeutics.com

SRNE key statistics

Market cap
110.26K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
74.10K
Volume
57.25K
Open price
$0.0002
High today
$0.0029
Low today
$0.0002
52 Week high
$0.016
52 Week low
$0.00

Sorrento Therapeutics (SRNE) at a glance

As of Oct 20, 2026, Sorrento Therapeutics (SRNE) shares are priced at $0.0008, giving the company a market cap of 110.26K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0002 and $0.0029. The current price is 300.0% above the day's low and 72.4% below its high.

Volume so far is 57.25K shares, below the average of 74.10K shares a day.

Over the past year Sorrento Therapeutics has ranged from $0.00 to $0.016, and now sits 5% of the way up that range.

Sorrento Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q1 FY23 it reported -$0.26 per share against an estimate of -$0.1632.

SRNE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 23.1% on average.

  1. Q1 FY21: reported $0.01 per share against an estimate of $0.3842
  2. Q2 FY21: reported -$0.57 per share against an estimate of -$0.204
  3. Q3 FY21: reported -$0.40 per share against an estimate of -$0.2346
  4. Q4 FY21: reported -$0.47 per share against an estimate of -$0.3009
  5. Q2 FY22: reported -$0.54 per share against an estimate of -$0.255
  6. Q3 FY22: reported -$0.20 per share against an estimate of -$0.2601
  7. Q4 FY22: reported -$0.4617 per share against an estimate of -$0.1938
  8. Q1 FY23: reported -$0.26 per share against an estimate of -$0.1632

Similar companies

Companies in the same industry as Sorrento Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.